{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:27:53Z","timestamp":1768296473301,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR4021"],"award-info":[{"award-number":["SHDC2020CR4021"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017536","name":"Shanghai Pulmonary Hospital","doi-asserted-by":"crossref","award":["FKLY20011"],"award-info":[{"award-number":["FKLY20011"]}],"id":[{"id":"10.13039\/501100017536","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, riociguat, a soluble guanylate-cyclase stimulator is recommended by international guidelines. More recently, balloon pulmonary angioplasty (BPA) develops as an alternative treatment for inoperable CTEPH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This study is a single-center randomized controlled trial. Subjects with inoperable CTEPH are randomized into either a BPA combined with riociguat or riociguat monotherapy group (2:1) and observed for 12\u2009months after initiation of treatment. The primary endpoint is the change in pulmonary vascular resistance from baseline to 12\u2009months after initiation of treatment. The secondary endpoints include 6-min walk distance (6MWD), WHO-FC, NT-proBNP, SF-36, and other hemodynamic parameters. Safety endpoints are analyzed too.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study aims to compare the efficacy and safety of BPA combined with riociguat and riociguat monotherapy for inoperable CTEPH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/edit.aspx?pid=52923&amp;htm=4\">ChiCTR2000032403<\/jats:ext-link>. Registered on 27 April 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05910-5","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T11:05:55Z","timestamp":1640603155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Qin-Hua","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Gang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ci-Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"issue":"1","key":"5910_CR1","doi-asserted-by":"publisher","first-page":"1801915","DOI":"10.1183\/13993003.01915-2018","volume":"53","author":"NH Kim","year":"2019","unstructured":"Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. https:\/\/doi.org\/10.1183\/13993003.01915-2018.","journal-title":"Eur Respir J."},{"issue":"2","key":"5910_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1378\/chest.81.2.151","volume":"81","author":"M Riedel","year":"1982","unstructured":"Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81(2):151\u20138. https:\/\/doi.org\/10.1378\/chest.81.2.151.","journal-title":"Chest."},{"issue":"1","key":"5910_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J."},{"key":"5910_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2018.08.079","volume":"272S","author":"H Wilkens","year":"2018","unstructured":"Wilkens H, Konstantinides S, Lang IM, Bunck AC, Gerges M, Gerhardt F, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:69\u201378. https:\/\/doi.org\/10.1016\/j.ijcard.2018.08.079.","journal-title":"Int J Cardiol."},{"key":"5910_CR5","unstructured":"Working Group on Pulmonary Vascular Diseases of Chinese Society of Cardiology of Chinese Medical A, Editorial Board of Chinese Journal of C. [Chinese guidelines for the diagnosis and treatment of pulmonary hypertension 2018]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46:933\u201364."},{"issue":"18","key":"5910_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","volume":"124","author":"J Pepke-Zaba","year":"2011","unstructured":"Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.015008.","journal-title":"Circulation."},{"issue":"3","key":"5910_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","volume":"141","author":"E Mayer","year":"2011","unstructured":"Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141(3):702\u201310. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.11.024.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"21","key":"5910_CR8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","volume":"71","author":"E Mahmud","year":"2018","unstructured":"Mahmud E, Madani MM, Kim NH, Poch D, Ang L, Behnamfar O, et al. Chronic Thromboembolic Pulmonary Hypertension: Evolving Therapeutic Approaches for Operable and Inoperable Disease. J Am Coll Cardiol. 2018;71(21):2468\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.009.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"5910_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1183\/09031936.00039808","volume":"33","author":"F Grimminger","year":"2009","unstructured":"Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33(4):785\u201392. https:\/\/doi.org\/10.1183\/09031936.00039808.","journal-title":"Eur Respir J."},{"issue":"20","key":"5910_CR10","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.981738.","journal-title":"Circulation."},{"issue":"4","key":"5910_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1209657.","journal-title":"N Engl J Med."},{"issue":"5","key":"5910_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1183\/09031936.00087114","volume":"45","author":"G Simonneau","year":"2015","unstructured":"Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293\u2013302. https:\/\/doi.org\/10.1183\/09031936.00087114.","journal-title":"Eur Respir J."},{"issue":"19","key":"5910_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/heartjnl-2012-303549","volume":"99","author":"AK Andreassen","year":"2013","unstructured":"Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart. 2013;99(19):1415\u201320. https:\/\/doi.org\/10.1136\/heartjnl-2012-303549.","journal-title":"Heart."},{"issue":"6","key":"5910_CR14","doi-asserted-by":"publisher","first-page":"1602409","DOI":"10.1183\/13993003.02409-2016","volume":"49","author":"KM Olsson","year":"2017","unstructured":"Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J. 2017;49(6):1602409. https:\/\/doi.org\/10.1183\/13993003.02409-2016.","journal-title":"Eur Respir J."},{"issue":"42","key":"5910_CR15","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/eurheartj\/ehx530","volume":"38","author":"T Aoki","year":"2017","unstructured":"Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. Eur Heart J. 2017;38(42):3152\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehx530.","journal-title":"Eur Heart J."},{"key":"5910_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejrad.2016.12.013","volume":"89","author":"T Ogo","year":"2017","unstructured":"Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, et al. Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. Eur J Radiol. 2017;89:270\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2016.12.013.","journal-title":"Eur J Radiol."},{"issue":"5","key":"5910_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1183\/09031936.00012914","volume":"43","author":"S Fukui","year":"2014","unstructured":"Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394\u2013402. https:\/\/doi.org\/10.1183\/09031936.00012914.","journal-title":"Eur Respir J."},{"issue":"3","key":"5910_CR18","doi-asserted-by":"publisher","first-page":"204589401878399","DOI":"10.1177\/2045894018783996","volume":"8","author":"CB Wiedenroth","year":"2018","unstructured":"Wiedenroth CB, Ghofrani HA, Adameit MSD, Breithecker A, Haas M, Kriechbaum S, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ. 2018;8(3):2045894018783996. https:\/\/doi.org\/10.1177\/2045894018783996.","journal-title":"Pulm Circ."},{"key":"5910_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijcard.2016.06.331","volume":"221","author":"T Tsugu","year":"2016","unstructured":"Tsugu T, Murata M, Kawakami T, Kataoka M, Nagatomo Y, Tsuruta H, et al. Amelioration of right ventricular function after hybrid therapy with riociguat and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2016;221:227\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.331.","journal-title":"Int J Cardiol."},{"issue":"2","key":"5910_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028831","volume":"10","author":"T Kawakami","year":"2020","unstructured":"Kawakami T, Matsubara H, Abe K, Kataoka M, Kohsaka S, Sato Y, et al. Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study. BMJ Open. 2020;10(2):e028831. https:\/\/doi.org\/10.1136\/bmjopen-2018-028831.","journal-title":"BMJ Open."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05910-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T11:13:49Z","timestamp":1640603629000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05910-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5910"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05910-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is approved by the local ethics committee (EC) of Shanghai Pulmonary Hospital (L20-385-1). Participants in the study are required to read the information sheet and consent to participate in the trial. Written informed consent should be obtained from all participants after a full explanation of this study. The study protocol registers at the Chinese Clinical Trial Registry on 27 Apr 2020 (ChiCTR2000032403).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"957"}}